In conclusion, the present study demonstrated that elevated EHMT2 expression and activity in NSCLC may induce resistance to treatment with EGFR-TKI, indicating that EHMT2 may be a useful indicator of EGFR-TKI resistance in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.